Alendronate Sodium NDC 16714-633

NDC codes

FDA NDC Directory

Product NDC (as listed)16714-633Labeler and product segments. Claims need a package NDC.

Product NDC at billing width16714-0633Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
16714-633-01	16714063301	1 BLISTER PACK in 1 CARTON (16714-633-01) / 4 TABLET in 1 BLISTER PACKMarketed from Aug 4, 2008
16714-633-02	16714063302	5 BLISTER PACK in 1 CARTON (16714-633-02) / 4 TABLET in 1 BLISTER PACKMarketed from Aug 4, 2008
16714-633-11	16714063311	10 BLISTER PACK in 1 CARTON (16714-633-11) / 10 TABLET in 1 BLISTER PACK (16714-633-10)Marketed from Aug 4, 2008

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Alendronate Sodium
Generic name (nonproprietary): alendronate sodium
Active ingredients: Alendronate sodium — 70 mg/1
Dosage form: Tablet
Route: Oral
Labeler: NorthStar Rx LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 090124
Marketing start: Aug 4, 2008
Listing expires: Dec 31, 2027
Other FDA classes: Diphosphonates (Chemical structure)
Identifiers: Product ID 16714-633_aed28579-c63c-48b1-8b67-e24137d0709aSPL ID aed28579-c63c-48b1-8b67-e24137d0709aSPL set ID 4323d3aa-cbb0-41e2-aba7-7a94a0516993RxCUI 904396, 904419, 904431UNII 2UY4M2U3RAUPC 0316714631011, 0316714631110
Pharmacologic class: Bisphosphonate

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N416714063301 followed by a unit qualifier and the quantity

Package 16714-0633-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 12, 2026.

Indications (excerpt from the label)

Alendronate sodium is a bisphosphonate indicated for: Treatment and prevention of osteoporosis in postmenopausal women (1.1 , 1.2) Treatment to increase bone mass in men with osteoporosis (1.3) Treatment of glucocorticoid-induced osteoporosis (1.4) Treatment of Paget's disease of bone (1.5) Limitations of use: Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use. (1.6) 1.1 Treatment of Osteoporosis in Postmenopausal Women Alendronate sodium tablets are indicated for the treatment of osteoporosis in postmenopausal women. In postmenopausal women, alendronate sodium tablets increases bone mass and reduces…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)